Omnicell, Inc. — FY2021 Form 10-K Summary
Business context and reporting period
Omnicell provides medication-management automation, software, analytics, consumables, and related services to healthcare systems and pharmacies. It reports as a single operating segment. This annual report covers the fiscal year ended December 31, 2021; comparisons are primarily with FY2020. About 90% of FY2021 revenue came from the United States.
Key financial results
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Total revenue | $1.132 billion | $892.2 million | +27% |
| Product revenue | $812.5 million | $636.0 million | +28% |
| Services and other revenue | $319.5 million | $256.2 million | +25% |
| Gross profit / gross margin | $554.7 million / 49% | $413.3 million / 46% | Margin +3 points |
| Operating income / operating margin | $89.5 million / 7.9% | $35.5 million / 4.0% | Improved |
| Net income | $77.8 million | $32.2 million | More than doubled |
| Diluted EPS | $1.62 | $0.74 | Higher |
| Cash from operations | $231.8 million | $185.9 million | +25% |
Product bookings increased 21% to $1.217 billion. Backlog rose to $1.25 billion at year-end from $924 million; $439 million was long-term backlog. Management cautions that backlog is not necessarily indicative of future sales because customers may change configurations or installation schedules.
Cash and cash equivalents were $349.1 million at December 31, 2021, down from $485.9 million. Working capital was a $95.5 million deficit, versus $553.0 million positive a year earlier, principally because the convertible notes were classified as current after becoming convertible. Current assets/current liabilities were 0.9x, versus 3.0x. Investing cash outflow was $412.5 million, including $354.2 million net cash paid for acquisitions, $29.0 million in property and equipment, and $29.4 million in external software development.
The company had $575 million principal amount of 0.25% convertible senior notes due 2025; their balance-sheet carrying amount was $488.2 million, net of discount and issuance costs. The $500 million revolving facility had no borrowings at year-end, and the company reported compliance with its covenants. Note fair value was $1.085 billion. The notes were convertible during Q1 2022, and the company had elected to settle principal in cash, with excess conversion value payable in cash and/or shares at its option.
Material changes versus FY2020
- Revenue growth reflected stronger customer demand, particularly for automated dispensing systems; FY2020 had been affected by pandemic-related customer delays and reduced activity.
- Gross margin improved with higher volume and scale, partly offset by inflation-related inventory costs in the second half of 2021.
- Operating expenses rose 23% to $465.1 million, led by higher employee-related costs, acquired-company expenses, amortization, and spending that had been curtailed during 2020.
- Net interest and other expense increased to $23.5 million, primarily from amortization of the convertible-note discount and issuance costs.
- SaaS, subscription software, and technology-enabled services revenue increased to $112.5 million from $53.8 million, reflecting acquired businesses and growth in services.
- Cash declined despite higher operating cash flow, primarily due to acquisition spending.
Outlook, risks, contingencies, and unusual items
Management describes continued investment in its cloud-based platform and its Autonomous Pharmacy strategy, with opportunities in point-of-care automation, central pharmacy, specialty pharmacy and 340B services, and retail pharmacy software. The filing does not provide a clear numerical FY2022 revenue or earnings forecast.
Management said customers’ purchasing patterns had returned toward pre-pandemic levels and continued through 2021, but the pandemic’s future effects remained uncertain. Risks highlighted include supply constraints and inflation—particularly semiconductor shortages—installation delays, healthcare customer budgets, competition, acquisition integration, subscription adoption and revenue timing, cybersecurity and privacy compliance, and regulatory or legal changes affecting 340B services. The company also noted dependence on limited or single-source suppliers.
FY2021 acquisitions included FDS Amplicare (base purchase price $177 million), ReCept ($100 million), and MarkeTouch Media ($82 million), expanding retail pharmacy software, patient engagement, and specialty pharmacy services. Integration and realization of expected benefits remain risks. Goodwill and intangible assets totaled approximately $1.017 billion at year-end; the company reported no goodwill impairment.
Legal matters included a BIPA class action that had reached a settlement agreement, with preliminary court approval in February 2022 and final approval still pending, and a trade-secret lawsuit brought by Becton, Dickinson and Company. The company recorded no material accrual for these matters, stating that any potential material loss was not considered probable and that a loss range could not be reasonably estimated or was not deemed material.
The auditors issued unqualified opinions on the financial statements and internal control over financial reporting. They identified inventory valuation, capitalized software costs, and acquired customer-relationship intangibles as critical audit matters.
Important facts for investors to verify
- Whether the large backlog converts to installed equipment revenue on schedule, and whether installation capacity or component shortages constrain conversion.
- Whether revenue and margins remain resilient as semiconductor, freight, and other input costs evolve.
- Whether acquisitions deliver expected growth and service revenue without impairments or integration disruption.
- The notes’ conversion status, cash requirements, potential dilution, and effect on reported working capital after December 31, 2021.
- Developments in the BIPA settlement and BD trade-secret litigation, and any resulting financial exposure.
- Whether growth in recurring subscription and cloud revenue translates into sustainable cash generation and profitability.